Empirico Stock

Empirico is a developer of an insights platform designed to turn biological insights from human genetics into new medicines.

Sign up today and learn more about Empirico Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Empirico Stock

Empirico is a developer of an insights platform designed to turn biological insights from human genetics into new medicines.The company's platform uses biological datasets, human genetics, and programmable biology to power target discovery and development, enabling scientists to systematically generate, interrogate, and prioritize high-confidence therapeutic hypotheses.

Funding History

November 2018$12.5M
December 2019$17.0M
January 2020$17.0M
March 2023$45.2M

Management

CEO

Omri Gottesman

Associate Director

John Vekich

Head of Therapeutic Chemistry

David Rozema

Head of Strategy

Andrew Spencer

Head of Operations

Anggie Becorest

Head of Data and Engineerin & Co-Founder

Brian Cajes

Head of Discovery

Shannon Bruse

Head of Therapeutic Development

David Lewis

Director

PJ Buske

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo